RxDoctor Payments Data

Sanam Loghavi, MD

Anatomic Pathology & Clinical Pathology · Houston, TXNPI 1871802199

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $70,465 of the $94,148 with a category attached, or 74.8%. 17 manufacturers reported payments, led by Daiichi Sankyo Inc. at 27.3% of the total. Among anatomic pathology & clinical pathology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$94,148in general payments, 2019–2025

Across 123 payments — averaging $765.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$26K
  • Servier Pharmaceuticals LLC$20K
  • AbbVie$14K
  • Bristol Myers Squibb$10K
  • Stemline Therapeutics Inc.$7K
  • Syndax Pharmaceuticals, Inc.$7K
  • plus $11K from 11 others

What the payments were for

  • Consulting fees$70,46575%
  • Speaking & faculty fees$2,9393%
  • Travel & lodging$16,32317%
  • Food & beverage$4,3635%
  • Education$590%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,148 in reported general payments places this provider in the 95th percentile of 736 anatomic pathology & clinical pathology providers in Texas.

See all anatomic pathology & clinical pathology providers in Texas

Medicare billing

Part B allowed, 2024
$47,676
Medicare patients
606
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →